John Leite, an insider at Veracyte Inc (VCYT), sold 82,113 shares of the biotechnology company on December 3, 2025, at a price of $47.51 per share, totaling approximately $3.90 million. Following this transaction, Leite retains 82,113 shares in the company.
Insider sales can occur for various reasons, including diversification, tax planning, or personal financial needs. While significant selling activity may attract attention, routine sales do not inherently suggest negative sentiment toward the company. Investors are advised to consider insider transactions as one of many factors when evaluating a company's performance.
Veracyte, headquartered in South San Francisco, California, focuses on the research, development, and commercialization of diagnostic products. The firm employs 824 full-time staff and went public on October 30, 2013. With a market capitalization of $3.3 billion, Veracyte's P/E ratio stands at 125.14, and its EPS is 0.33. The company provides cancer diagnostic tests, leveraging extensive genomic and clinical data through its advanced Veracyte Diagnostics Platform.
Looking ahead, Veracyte is scheduled to report earnings on May 5, 2026, with an expected EPS of $0.23 and revenue of $132.8 million. This update provides insight into the ongoing activities of Veracyte's insiders, which may be viewed alongside broader market trends and company fundamentals.